FUSMobile tops 1,000 Neurolyser XR patients across eight countries

FUSMobile said its Neurolyser XR focused ultrasound system has now treated more than 1,000 patients in eight countries, including the U.S. and Canada. The milestone signals growing physician adoption of a non-invasive option for chronic pain treatment.

Why it matters: - FUSMobile is pushing a non-invasive chronic pain treatment into broader clinical use. - More than 1,000 treated patients across eight countries suggests expanding physician adoption and growing market validation for focused ultrasound. - The company is positioning Neurolyser XR as an incision-free alternative to procedures that require needles or surgical entry.

What happened: - FUSMobile said in July 2026 that more than 1,000 patients have now been treated worldwide with the Neurolyser® XR system. - The milestone spans eight countries, including the United States and Canada. - The company said the figure comes from clinical utilization data tied to Neurolyser XR treatment consumables supplied to healthcare providers. - Chief Executive Officer Dr. Arik Hananel called the milestone a validation of the technology and said the international spread reflects physician confidence. - President Ron Aginsky said the expansion shows growing worldwide interest in non-invasive pain management technologies.

The details: - Neurolyser XR uses focused ultrasound energy guided by fluoroscopic imaging to create therapeutic thermal lesions. - The system is designed to avoid needles, probes and surgical incisions. - FUSMobile says the platform gives physicians a non-invasive option for chronic pain when precise thermal ablation is clinically indicated. - The company says the technology can reduce procedure complexity and patient recovery time. - Since its commercial launch, Neurolyser XR has expanded into clinical and commercial sites across North America and internationally. - The company says the treatment is delivered entirely from outside the body, unlike conventional radiofrequency ablation that requires needle placement. - FUSMobile’s Neurolyser platform combines imaging guidance with precision-focused ultrasound energy for incision-free treatment without needles or implants. - FUSMobile develops image-guided focused ultrasound technologies for chronic pain and other medical conditions.

Between the lines: - The 1,000-patient mark gives FUSMobile a concrete commercial metric as it competes for acceptance in pain medicine. - The emphasis on eight-country use suggests the company wants to frame Neurolyser XR as a global platform, not just a U.S. product. - The forward-looking language in the release signals that broader adoption is still an objective, not a finished outcome.

What's next: - FUSMobile said it will keep supporting physicians, expanding clinical evidence and making the technology available to more patients globally. - The company believes the milestone is another step toward mainstream use of focused ultrasound for chronic pain. - More information is available at the company's announcement.